Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase 1 trial (BB-IND 6274)

Human Gene Therapy

Volumn 7, Issue 16, 1996, Pages 2047-2057

  Treat, Joseph ^a   Kaiser, Larry R ^a   Sterman, Daniel H ^a   Litzky, Leslie ^a   Davis, Alan ^a   Wilson, James M ^a   Albelda, Steven M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ADVANCED CANCER; ARTICLE; CANCER THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; EXPRESSION VECTOR; GENE THERAPY; HUMAN; MAXIMUM PERMISSIBLE DOSE; MESOTHELIOMA; PHASE 1 CLINICAL TRIAL; ROUS SARCOMA ONCOVIRUS; VIRUS RECOMBINANT;

ADENOVIRIDAE; ONCOVIRINAE; ROUS SARCOMA VIRUS;

EID: 0029799294     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.16-2047     Document Type: Article

References (16)

1. Antman K, et al. Malignant Mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience Over two decades, 1965-1985. J Clin Oncol 6(1):147-153, 1988
2. McCormack P, Nagasaki F, Hilaris BS, et al: Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Surg 84:834, 1982
3. Hillerdal G: Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321-343, 1983
4. Culver KW, Ram Z, Wllbridge, Ishii H, Oldfield EH, Blaese RM. In Vivo gene Transfer with retroviral vector-producer cells for treatment of experimental brain tumors, Science, 256: 1550-1552.
5. Moolten FL, Wells JM, Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Canc Inst, 82:297-300, 1990.
6. Moolten FS, Wells JM, Mroz PJ, Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced Herpes Thymidine kinase genes. Cancer Letters, 64:257-263, 1992.
7. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The "Bystander Effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Research, 53:5274-5283, 1993.
8. Hasegawa Y, Emi N, Shimokata K, Abe A, Kawabe T, Hasegawa T, et al. Gene Transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer lines using retroviral vectors. Am J Resp Cell Mol Bio, 8:655-661, 1993.
9. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, Klatzmann D. Regression of established macroscopic liver metastases after in situ tTransduction of a sucide gene. Proc Natl Acad Sci, 90:7024-7028, 1993.
10. Ram Z, Culver KW, Walbridge, Blaese, Oldfield EH, In Situ Retroviral-Mediated Gene Transfer for the treatment of brain tumors in rats. Cancer Research 53:83-88, 1993.
11. Mulligan RC. The basic science of gene therapy. Science, 26:926-932, 1993.
12. Smythe WR, Kaiser LR, Amin KM, Pilewski JM, Eck S, Wilson JM, Albelda SM. Successful adenovirus mediated gene transfer in an In Vivo Model of Human malignant mesothelioma. Ann. Thor. Surg. 57:1395-401, 1994a.
13. Smythe WR, Hwang HC, Amin KM, Eck SJ, Wilson JM, Kaiser LR, Albelda SM, Recombinant adenovirus transfer of the HSV-thymidine kinase gene to thoracic neoplasms. Cancer Research, 54:2055-2059, 1994b.
14. Smythe, W.R., Hwang, H.C., Elshami, A.A., Amin, K.M., Eck, S.L., Davidson, B.L., Wilson, J.M., Kaiser, L.R., Albelda, S.M. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Annals of Surgery, 222:78-86, 1995.
15. Hwang, H.C., Smythe, W.R., Elshami, A.A., Kucharczuk, J.C., Amin, K.M., Williams, J.P., Litzky, L.A., Kaiser, L.R., Albelda, S.M. Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer. Am. J. Resp. Cell Molec. Biol., 13:7-16, 1995.
16. Kozarsky KF and Wilson JM. Gene therapy: adenovirus vectors. Current Opinion in Genetics and Development, 3:499-503, 1993.